Achieving long-term continuous blood naltrexone and 6-ß-naltrexol coverage following sequential naltrexone implants
| Autor: | Robert C Hansson, C-T Chan, Diane Arnold-Reed, George O'Neil, Gary K. Hulse |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Narcotic Antagonists Medicine (miscellaneous) Drug Administration Schedule Naltrexone Body Mass Index Heroin Cohort Studies medicine Humans Retrospective Studies Drug Implants Pharmacology Heroin Dependence business.industry Follow up studies Middle Aged Surgery Beta-naltrexol Psychiatry and Mental health Multicenter study Delayed-Action Preparations Anesthesia Female Implant business Clinical record Follow-Up Studies medicine.drug |
| Zdroj: | Addiction Biology. 9:67-72 |
| ISSN: | 1355-6215 |
| DOI: | 10.1080/13556210410001674112 |
| Popis: | The aim of this study was to assess blood free naltrexone and 6-beta-naltrexol levels with time following treatment with sequential sustained-release naltrexone preparations. Data were collected from blood samples analysed independently for naltrexone and 6-beta-naltrexol and from clinical record review at a community heroin treatment clinic in Perth, Western Australia. Five patients received sequential 3.4 g (3.49+/-0.01 g and 3.36+/-0.05 g, respectively) naltrexone implants. The second implant was received on average within 131.2+/-15.67 days of the first implant. The mean length of follow-up was 307.2+/-18.28 days of the first implant. Blood naltrexone levels have the potential to remain above 2 and 1 ng/ml for a total of 390 and 524 days, respectively, and blood 6-beta-naltrexol was maintained above 10 ng/ml for a total of 222 days following insertion of these implants. No patient relapsed to dependent heroin use during the implant coverage period while blood naltrexone concentrations were above 2 ng/ml. Results indicate that blood naltrexone and 6-beta-naltrexol levels can be maintained above therapeutic levels for prolonged periods following use of sequential 3.4 g naltrexone implants. These extended periods of coverage will offer significant benefits for managing the heroin-dependent patient. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|